leukocytes or in the neutrophil fraction, where cystine storage occurs selectively in cystinosis, did not occur (Table 3) as a possible explanation for these findings; nor did storage of samples, a possible artifact, influence the cystine content of cystinotic cells (Fig. 2) .
Multiple site rectal mucosa biopsy clearly revealed cystine storage but serial biopsies did not reflect a positive DTT response when compared with the leukocyte assay (Table 4) . High intersample variation in cystine content, even between samples taken at one time, prevented measurement of a treatment response.
DTT had no apparent detrimental effect on the concentration of representative proteins, including hemoglobin (Table 3) , serum insulin, and serum immunoglobulin during the treatment trials. Renal function (glomerular and tubular) was severely depressed and did not improve during the period of observation in either patient (Table 2 ; Fig. 3, A and B) .
Postmortem tissues from one patient revealed 10-40-fold excess cystine accumulation in kidney cortex and liver (Table 5) . However, these levels of accumulation are at the lower range of or even below published values for cystine in cystinotic kidney and liver.
Whereas chemical methods are not reliable for detecting and measuring DTT in biologic fluids, preliminary evidence indicates that a silylated derivative of oxidized D I T can be detected in the urine of patients receiving DTT by mouth (Fig. 4) . This finding suggests that the thiol is absorbed and excreted.
Speculation
The defect in cystine metabolism (or transport) in cystinosis remains unknown. However, if administered early in the course of INC, DTT might prevent the occurrence of irreversible phenotypic components by preventing cystine accumulation.
Infantile nephropathic cystinosis is a fatal autosomal recessive inborn error of cyst(e)ine metabolism (20, 23) . Adolescent nephropathic cystinosis (1, 8 , 15) and adult benign cystinosis (15, 18, 23) are considered to be variants, perhaps allelic, of the infantile type, in which a more benign clinical course appears to correlate with less extensive intracellular, presumably lysosomal, storage of cystine. Dietary methods of treatment do not offset the unknown intracellular defect of cyst(e)ine metabolism and, accordingly, do not alter the clinical course of INC (2) . On the other hand, we have shown (1, 7, 8) that the sugar thiol, threo-2,3-dihydroxy-l,4-dithiolbutane (dithiothreitol or DTT), penetrates the living cell and will correct the abnormal cystine storage in cultured cystinotic fibroblastsit1 vifro. Earlier indications that DTT could be administered to human subjects (7) led us to examine the effect of long term administration of DTT in two patients with INC. Our results indicate that DTT, or equivalent thiols, might offer somc hope in the treatment of this inborn error of cystine storage.
MATERIALS AND METHODS

PATIENTS
Two 8-year-old boys (SL and P F ) , both in the late stages of INC, were enrolled in June 1973 in a trial of DTT treatment, under conditions of informed parental consent. Typical findings concerning growth failure, cystine storage, and renal failure were evident in both patients (Table I) . SL died of renal failure at 9 711 2 years during the later stages of this investigation. PF is still alive at 11 years (in April 1976). Previous observations on their fibroblasts and leukocytes are compatible with the INC phenotype (half-cystine content exceeded 8 nmol.mg-' protein in both patients). Patient PF has experienced 3 cm of linear growth between the 20th and 32nd month of the study, coinciding with the second DTT trial; there was no change in height during the first 20 months. No increase in height occurred in the other subject.
PROTOCOL
The investigation consisted of two periods of DTT treatment separated by an interval without DTT Parirnr SL Parirnr PF Leukocytes were separated from whole blood by drawing 10 ml venous blood into a syringe containing a mixture of dextran (2 ml) and heparin (1 ml) (5). After standing upright for 45 min at 37" the supernatant fluid containing leukocytes was discharged into a tube. The remaining erythrocytes were then removed by differential hypotonic lysis; leukocytes were recovered as a button after centrifugation and stored at -20" ' Data pooled from observations in prcvious 36 months; "control" immediately with 2.0 ml sulfosalycilic acid (3% wlv). The cyssamples obtained immediately before first treatment trial with DTT were tine-containing supernatant was separated by centrifugation at lost in laboratory accident. 27 ,000 X g for 20 min, and stored at -20" until analysis. 
Biopsy o f rectal mucosa was performed with a Rubin tube at ?-month intervals in the initial phases of the study. Multiple samples of rectal mucosa (3-7 Ing each) were obtained. from different sites which wcre individually homogenized and then deproteinized as described for leukocytes.
Samples of tissues obtained at autopsy from SL were stored intact at -20° until they wcre homogenized in distilled water. and then dcproteinized as described above.
ANALYSIS OF SAMPLES
Protein was analyzed by the method of Lowry ?t ul. (1 3). Halfcystine was analyzed by elution chromatography on ion exchange resin columns by the method of Spackman. Stein, and Moore (24) on a modified Beckman-Spinco amino acid analyzer fitted with an expanded range recorder (4.5-5.0 ml) (22) . The reproducibility of half-cystinc analysis on our analyzer is ?3.5 % by this method. Creatinine (3) and urea nitrogen (14) were ~neasured by standnrd automated methods on a Technicon analyzer.
GAS CHROMATOGRAPHY OF DITHIOTHREITOL
Aliquots of urinc (about 5 0 ml), obtained from patietlt PF during periods when Dm' was either administered by mouth or withheld. wcre evaporated almost t o dryness in a Buchlcr flash evaporator. Ethanol (99%. 1 0 ml) was added to the conccntratcd urine. allowed to chill at 4". and spun at 4,500 x g for 10 min in a refrigerated centrifuge (Sorvall RC2-B). The supernatant was removed and the ethanol evaporated off under a nitrogen stream overnight. DTT powder (>YY% in the thiol form) was dissolved in ethanol and partially oxidized in air t o the disulfide. A mixture of DTT and urine was also prepared.
A large excess of N.0-his-(trimethylsily1)-mtamidc (BSA) was added to the samples (0.1 ml to a few crystals of DTT powder; 1 . 0 ml to the urine precipitate). since we were unable to prepare a completely anhydrous urine precipitate. The sample containing BSA was then heated at 60" for 5 nlin. An aliquot ( 3 p1) was injected into an LKB 9000 gas chromatograph-mass spectrometer. The conditions for analysis were: stationary phase. a glass column ( 6 by 114 inch) containing O V 101 on Chromosorb W;' gas phase. helium. flow rate 3 5 ml.min I ; column temperature progranimed from YO0-280" with an increase of 5"lmin; injector temperature, 280"; separator tcmperature. 280"; ion source temperature, 270"; ionization energy, 70 e v .
PRESENTATION OF DATA
The sequential leukocyte half-cystine values are presented in tabular form and also by the neth hod of cumulative sum analysis (CUSUM) (9). This method makes possible assessment of trends in the treatment response from serial data collected at intervals. CUSUM plots dilute background analytic "noise" and indicate significant changes which might not be detectable initially in a plot with random variation from the mean. In the present long term study we found this technique of considerable use to monitor the response to DTT. Consistent trends which are not initially evident from tabulations of primary data can be revealed clearly by CUSUM analysis (9) . In order to use C U S U M analysis, however. it is necessary to deterrnine a relevant baseline. In the absence of any information about the "normal" range for a particular measurement it is necessary to select a baseline re- tlccting the quasisteady state. T h e baseline for leukocyte halfcystine concentration in the first phase of the investigation was chosen by averaging three values at the end of the first cycle o f treatment; successive deviations (positive o r negative) from this baseline were summed and plotted according to the C U S U M mcthocl. ( A pretreatment baseline was not available because a laboratory accident caused the loss of samples collected just before the first treatmcnt pcriod.) A second baseline was chosen a t the e n d of the period of D71T withdrawal a n d beforc the second treatment period. to evaluate the effect of the second treatment regimen. T h e three last values in the withdrawal period were averaged for this baselinc. and subseclucnt deviations from it were s u~n n~e c l c~l~n u l a t i v e l y a n d plotted. 
RESULTS
CLINICAL. STATUS
N o overt signs of toxicity t o DTT were observed o t h e r than nausea a n d vomiting a t the uppermost dosage. Melena was absent. Serum insulin levels were not depressed hy DTT a n d inimunoglobin levels remained normal. protein) ( I S ) . in both patients before treatment with DTI' (Table I ) . Leukocyte cystine fell during D T T treatment in both patients, then increased during the phase of DTT withdrawal and diminished again during the second period of DTT treatment (Table 3 ; Fig. I . A and B ) . C'ystine accumulation does not occur in circulating lymphocytes in cystinosis (31). We pcrformed differential cell counts in the course of our study to determine whether the apparent decline in leukocytc cystine during D T T trcatnient was caused by a relative decline in the neutrophil fraction. The differential and total leukocyte counts did not alter significantly throughout the period of observation (Table 3 ) . Another factor known to modify cellular cystine content is storage of cells. Kroll and colleagues ( 12) observed that the halfcystinc content of cystinotic fibroblasts fell by half in the initial few days of storage of cell pcllcts at -20" or 7 0 " . During the first D7T trial in our study. leukocytes were stored as pellets for periods up to 180 days before analysis. In the present study, the concentration of half-cystine is clearly influenced more by the duration of D T T trcatment than by the duration of cell storage beforc cystinc analysis (Fig. 2) . Nonetheless. in order to guard u that this observi~tion is not an artifact of sample handling.
Rectal mucosa can be used for the diagnosis of cystinosis (10). However. even with biopsies from multiple mucosal sites, we did not find the technique useful to monitor the response to D T T in the first trial. lntersarnple variation in cystinc content was very great even among samples taken froni a paticnt on the same day; and also from one time to thc next ('l'able 4). Accordingly, we did not pursue these observations in the second trial of D7T treatment.
Slit lamp examination of cystinc content in cornea was also evaluated in our patients as a monitor of trcatlncnt response. Photographs taken unclcr standardized conditions to cstimate the density of crystals rcvealcd n o apparent change in the course of the present study.
ON DTT
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Renal function was monitored by serum creatinine concentration. endogenous creatinine clearance. and various indicators of tubular function in cystinosis. as described previously (8) of observation. However, in both patients, there was some apparent attenuation in the progress of renal failure during the first D T T trial as reflected in serum creatinine values (Table 2 ; Fig. 3 , A and B) . This finding was not evident in the second trial.
There was n o change in the abnormal urinary composition associated with cystinosis.
POSTMORTEM TISSUE CYSTINE
T h e half-cystine content of frozen, postmortem tissues was examined in patient SL (Table 5 ) . Solid tissues were stored at -20" until their cystine content was measured; storage under these conditions does not appear t o affect the determination of cystine. T h e half-cystine content of brain was not elevated. a finding which has been reported previously in cystinosis (19, 20) . T h e half-cystine content of kidney was greatly elevated; however, the observed values (Table 5 ) were distributed at the lower e n d of the range for postmortem values in ICN kidney (1 9 . 20). Half-cystine content of liver from o u r patient who had been treated with D T T was lower than in other samples of cystinotic liver known t o us (Table 5 ) .
MEASUREMENT O F DTT IN BODY FLUIDS
We were unable t o measure D T T accuratcly in urine a s a yellow chromophore at 412 nm (25) when it is reacted with Ellman's reagent (5,s'-dithiohisl2-nitrobcnzoic acid]. D T N B ) after reduction with sodium borohydride (6). Poor sensitivity of the assay and poor recovery of D T T in urine were responsible. G a s chromatography ( G C ) proved to b e a more promising method of analysis.
T h e G C scan of the solution containing a mixture of oxidized and reduced D T T showed two main peaks. T h e o n e for oxidized D T T eluted early ( 9 min) a t 190" while the reduced form eluted later (13.5 min) at 220".
T h e urine sample from patient PF obtained when he was receiving D T T , revealed many peaks o n the GC scan (Fig. 4 ) . However. a peak with a retention time of 9 min coincided with the bis-trimethylsilylatcd derivative of cyclic (oxidized) D T T ; oxidi7ed DTT standard and urine peak coeluted. Any reduced D T T that might have been present in urine was masked by glucose and other monosaccharides; however, reduced D T T was not observed in this region even when the mass spectra of eluted urine material were compared with the mass spectrum of a standard. D T T (oxidized o r reduced) was not detected in urine when the patient was not receiving the substance.
T h e mass spectrum of cyclic D T T (disulfide) standard is also identical t o the substance presumed to b e DTT (disulfide) in the urine sample. T h e molecular ion of D T T is evident a t m/e (mass/ charge) 296 with intensity of 2 3 . 7 % related to the most intense base peak a t m/e I 16. These findings indicate that D T T can be detected a s disulfide in urine by gas chromatography. Urine contains D T T . which is in the oxidized form. when the patient is receiving D T T by mouth.
DEPAPE-BRIGGER ET A L
DISCUSSION
may be able to respond to DTT. despite our negative finding
The present study provides initial evidence that the abnormally elevated endogenous cystine content in INC can be diminished i t t v i v o by orally administered D T T . The thiol promotes a decrease in cystine concentration in peripheral leukocytes (neutrophils). During the first treatment period, leukocyte half-cystine concentration decreased in both of our patients; it then increased when D T T was withdrawn. and again diminished in the second treatment period. The decrease in leukocyte halfcystine was not accounted for by a preferential decline in the neutrophil fraction of peripheral blood leukocytes during exposure to DTT. Leukocytes were stored at -20'. as intact cell pellets. up to 180 days during the first treatment period. Although the halfcystinc content of intact INC fibroblasts diminishes during storage (12) . our data indicate that storage of intact leukocytes was not the cause of their diminished half-cystinc content in the present study. Accordingly. we believe this change was probably an effect of D T T administration which has been shown in v i r r o to deplete the cystine excess of cystinotic tissues ( 1 . 7. 8).
Although rectal mucosa biopsy and slit lamp examination of the cornea are both useful techniques for the diagnosis of cystinosis. neither method permitted us to observe a response to DTT when compared with the leukocyte response. Irregular cystinc deposition in rectal mucosa and wide intersample variation may explain the erratic quantitative results derived from the samples of rectal mucosa. However. the failure to observe a response in nonleukocyte tissues may indicate that D 7 T did not reach and act upon their cystine stores in contrast to its apparent ability to d o so in circulating leukocytes.
D T T will penetrate the plasma membrane of cells i t t r r i t r o ( 1 ) and, at 0.1 mM it1 v i t r o , it is taken up by tissues without adverse effect on tissue respiration o r upon membrane transport functions. Present evidence suggests that DTT and other thiols are probably maintained in the SH form by the intact cell (I 6 ) .
Accordingly. it was of interest to know whether DTT actually entered the body from the intestinal lumen in the present trial. O u r GC method indicates that oxidized D T T is excreted in the urine when it has been administered by mouth. implying that DTT is released from the enteric-coated capsules and ahsorhccl from the intestine in which case it may be available for uptake by leukocytes and perhaps also by solid tissues. D T T was tolerated it1 v i v o by our patients at the closage schedule used in the present study. No alterations in the plasma levels of proteins containing disulfide bonds ( c . g , , insulin and immunoglobulins) were observed in the present (6) and in our earlier study (1. 7). The lathyritic-like effect which has been experienced by patients receiving D-penicillamine ( I I ) was not observed in the present trial with DTT.
Other workers have observed an i t t v i v o leukocyte-cystine response to exogenous thiol administration (16) ; in those studies cysteamine was used. A trial with the nonthiol reducing agent. ascorbic acid. is also under way but the i t t b'ivo response to this agent is unknown at the present time (16).
Our findings suggest that D T T offers little hope for alteration of the natural course of INC in patients when nephropathy (or other tissue damage) is advanced. The apparent plateau effect in the deterioration of rcnal function during the first DTT trial in our patients (Fig. 3) was not repeated in the second trial; this first response may indeed be part of the natural process of the illness in its preterminal stages. In our case it was unlikely to be the result of any improved clinical management o r intervention since the frequency of observation and of patient visits did not change from the pre-DTT treatment routine.
It is likely that primary prevention of cellular cystine nccurnulation in the young patient will be required if the secondary and irreversible phenotypic events arc to be avoided. O u r postmortem studies in p r i t i r t t t SL, which reveal a rather low half-cystine content of kidney and liver by available standards for frozen postmortem samples of cystinotic tissue (References 4 , 17. and 20) . give us some hope that solid tissues. as well as leukocytes. obtained in this respect regarding rectal mucosa and the uveal tract. However. to determine whether the fatal course of I N C can be diverted o r arrested, it will be necessary to devise a more palatable form of medication. o r an alternate route of D T T administration, so that further studies in younger patients can be pursued.
CONCLUSION
If clinical prognosis in the various forms of cystinosis (infantile ncphropathic. adolescent nephropathic, and adult benign) is in any way related to the degree of abnormal intracellular accumulation of cystine. then depletion of the excess cystine stores in the nephropathic forms of cystinosis may ameliorate the disease process. We have studied the effect of the reducing thiol, dithiothreitol, given by mouth at doses not exceeding 25 mg/kg body weight. three times daily, in two patients with infantile nephropathic cystinosis. The half-cystine content of peripheral blood leukocytes was slowly decreased by D T T treatment; it then reaccumulated when D T T was not given; leukocyte kinetics did not otherwise seem to be perturbed by D T T . Rectal mucosa biopsies and corneal slit lamp examinations. albeit helpful for diagnosis, did not reveal a solid tissue response to thiol. Renal function did not improve during thiol treatment. No serious untoward effects were observed during 31 patient-treatment months with DTT. Silylation of oxidized D T T permitted its detection in urine of patients receiving the chemical by mouth, indicating absorption and excretion of the thiol.
